Search results for "Drugs"

showing 10 items of 747 documents

Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study

2020

The impact of COVID-19 on inflammatory bowel disease (IBD) patients under pharmacological immunosuppression is still not clearly understood. We investigated the incidence of COVID-19 and the impact of immunosuppression and containment measures on the risk of SARS-CoV-2 infection in a large IBD cohort, from a multicenter cohort from 21st of February to 30th of June, 2020. Ninety-seven patients with IBD (43 UC, 53 CD, one unclassified IBD) and concomitant COVID-19 over a total of 23,879 patients with IBD were enrolled in the study. The cumulative incidence of SARS-CoV-2 infection in patients with IBD vs. the general population was 0.406% and 0.402% cases, respectively. Twenty-three patients (…

medicine.medical_specialtyPopulationlcsh:MedicineInflammatory bowel diseaseArticledrugslaw.invention03 medical and health sciences0302 clinical medicinelawinflammatory bowel diseaseInternal medicinemedicineCumulative incidenceeducationeducation.field_of_studyimmunosuppressionbusiness.industryIncidence (epidemiology)lcsh:RCOVID-19General Medicinemedicine.diseaseIntensive care unitdigestive system diseasesPneumonia030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologybusinessCohort studyJournal of Clinical Medicine
researchProduct

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

2017

AbstractTherapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug…

medicine.medical_specialtyPsychopharmacologyGuidelines as Topic030226 pharmacology & pharmacy03 medical and health sciencesNeuropharmacology0302 clinical medicinePharmacotherapyHealth caremedicineHumansPharmacology (medical)PsychiatryIntensive care medicinePsychotropic Drugsmedicine.diagnostic_testbusiness.industryMental DisordersGeneral Medicinemedicine.disease3. Good healthAntiparkinson drugNeuropsychopharmacologySubstance abusePsychiatry and Mental healthTolerabilityTherapeutic drug monitoringDrug Monitoringbusiness030217 neurology & neurosurgeryPharmacogeneticsPharmacopsychiatry
researchProduct

Medications between psychiatric and addictive disorders

2016

International audience; Introduction : Many epidemiological studies have revealed a frequent co-occurrence of psychiatric and substance use disorders. The term used in the literature to refer to this co-occurrence is dual diagnosis. The high prevalence of dual diagnosis has led physicians to observe the effects of medication prescribed to treat psychiatric disorders on the co-occurring substance use disorder and vice versa. The concept of medications between psychiatric and addictive disorders stems from these clinical observations, alongside which, however, it has developed from the observation that both psychiatric and substance use disorders share common neurobiological pathways and trig…

medicine.medical_specialtyPsychotherapistSubstance-Related Disordersmedia_common.quotation_subject[SDV]Life Sciences [q-bio][ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthAddictionModafinilMirtazapine[ SCCO.PSYC ] Cognitive science/Psychology03 medical and health sciences0302 clinical medicineCognitionEpidemiology of child psychiatric disordersmedicineAnimalsHumansDual diagnosisMedical prescriptionPsychiatryClozapineBiological PsychiatryDepression (differential diagnoses)ComputingMilieux_MISCELLANEOUSmedia_commonPharmacologyPsychotropic DrugsDepressionAddictionmedicine.disease3. Good health030227 psychiatrySubstance abuseClinical researchSchizophreniaDiagnosis Dual (Psychiatry)[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health[SCCO.PSYC]Cognitive science/PsychologySchizophreniaDual diagnosisPsychologyPsychiatric disorders030217 neurology & neurosurgery
researchProduct

A common role for psychotropic medications: memory impairment.

2002

Summary The psychopathologic profile of mental disorders is very diverse and psychotropic medications used to treat them differ in their chemical structure. Nevertheless, these drugs share these four characteristics: delayed onset of clinical response, not one of them can be said to cure, there is a high number of non-responders, and the mechanism responsible for their therapeutic action is not known. It is hypothesized that the action of psychotropic medications is memory impairment, understanding memory as the trace left in the nervous system not only by individual experiences but also by genetic and epigenetic phenomena. It is suggested that it would be beneficial to translate some resea…

medicine.medical_specialtyPsychotropic DrugsTherapeutic actionMechanism (biology)Mental DisordersDelayed onsetBrainGeneral MedicineModels PsychologicalAntidepressive AgentsAction (philosophy)Research strategiesMemorymedicineCyclic AMPMemory impairmentHumansPsychologyPsychiatryClinical psychologyAntipsychotic AgentsSignal TransductionMedical hypotheses
researchProduct

Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk

2014

Statins are the first-line therapy in LDL-Cholesterol (LDL-C) reduction and its clinical use has contributed to significant prevention and treatment of atherosclerotic vascular disease. Yet, a significant proportion of patients remain at high risk. Recently, a number of new therapies have been developed to further lower LDL-C. These agents may provide clinical benefit on top of statin therapy in patients with high residual risk, severe hypercholesterolemia or as an alternative for patients who are intolerant to statins. We review four novel approaches based on the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein-B100 (apoB), Cholesteryl ester transport pro…

medicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BHypercholesterolemiaMipomersenFamilial hypercholesterolemiaBioinformaticschemistry.chemical_compoundRisk FactorsAnacetrapibInternal medicinemedicineHumansStatins Novel LDL-C lowering drugs Mipomersen Lomitapide Anacetrapib Evacetrapib PCSK9 inhibitorsbiologybusiness.industryAnticholesteremic AgentsPCSK9nutritional and metabolic diseasesLipid Metabolismmedicine.diseaseLomitapideResidual riskEndocrinologychemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessEvacetrapibCurrent Atherosclerosis Reports
researchProduct

Clinical review: impact of statin substitution policies on patient outcomes.

2009

Background. The increasing awareness of cost issues in health care has led to the increasing use of policy-driven substitution of branded for generic medications, particularly relative to statin treatment for cardiovascular diseases. While there are potential short-term health care savings, the consequences for primary care are under-researched. Our objective was to review data on intensive statin therapy and generic substitution in patients at high cardiovascular risk. Results. Current treatment guidelines for the prevention of cardiovascular disease are consistent in their recommendations regarding statin therapy and treatment targets. Clinical trials demonstrate that to reduce cardiovasc…

medicine.medical_specialtyStatinCost effectivenessmedicine.drug_classDiseasePlaceboReimbursement MechanismsRisk FactorsHealth caremedicineDrugs GenericHumanscardiovascular diseasesIntensive care medicinebusiness.industryPublic healthHealth Policynutritional and metabolic diseasesGeneral MedicineClinical trialEuropeCardiovascular DiseasesPractice Guidelines as TopicPhysical therapyObservational studylipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness
researchProduct

Effect of drugs of abuse on social behaviour: a review of animal models.

2015

Social behaviour is disturbed in many substance abuse and psychiatric disorders. Given the consensus that social behaviours of lower mammals may help to understand some human emotional reactions, the aim of the present work was to provide an up-to-date review of studies on the changes in social behaviour induced by drugs of abuse. Various animal models have been used to study the relationship between drugs of abuse and social behaviour. Herein, we describe the effects of different substances of abuse on the three most commonly used animal models of social behaviour: the social play test, the social interaction test and the resident-intruder paradigm. The first is the most widely used test t…

medicine.medical_specialtySubstance-Related Disordersmedia_common.quotation_subjectPoison controlNicotineDrug withdrawalmedicineAnimalsPsychiatrySocial Behaviormedia_commonPharmacologyBehavior AnimalAggressionIllicit DrugsAddictionMDMAmedicine.diseaseSocial relationSubstance abusePsychiatry and Mental healthModels Animalmedicine.symptomPsychologyClinical psychologymedicine.drugBehavioural pharmacology
researchProduct

Factores Asociados al Consumo Juvenil de Alcohol: Una Revisión desde una Perspectiva Psicosocial y Ecológica

2011

ResumenEl consumo abusivo de alcohol en la adolescencia es, en el momento actual, un importante problema de salud pública, hasta el punto de que su prevención se ha convertido en una de las prioridades en las políticas de salud. También, y en el ámbito de la intervención social, se ha venido estudiando, en los últimos años, los factores psicosociales implicados en ese consumo. En el presente trabajo se lleva a cabo una revisión de esos factores en el marco de la perspectiva ecológica, en la que se integran las variables psicológicas, relacionales y socioculturales. El consumo de alcohol es analizado como parte integrante de la cultura juvenil, despojando la explicación de contenidos patolog…

medicine.medical_specialtyadolescenciaSocial Psychologymodelo ecológicoContext (language use)drugsDevelopmental psychologyIntervention (counseling)Developmental and Educational PsychologymedicinedrogasSociocultural evolutionabusive alcohol consumptionApplied PsychologyConsumption (economics)alcoholPublic healthSocial environmentYouth cultureadolescenceecological modelPsychologySocial psychologyPsychosocialconsumo abusivo de alcoholPsychosocial Intervention
researchProduct

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwi…

2016

Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA wa…

medicine.medical_specialtyautoinflammatory disorders treatment interleukin (IL)-1 anakinra canakinumabDoseanakinra; autoinflammatory disorders; canakinumab; interleukin (IL)-1; treatmentautoinflammatory disorders; treatment; interleukin (IL)-1; anakinra; canakinumab030204 cardiovascular system & hematologyOff-label usecanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInternal medicinemedicinePharmacology (medical)Interleukin-1 inhibitorsAdverse effectOriginal Research030203 arthritis & rheumatologyPharmacologyAnakinratreatmentbusiness.industrylcsh:RM1-950Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin (IL)-1; Treatment; Pharmacology; Pharmacology (medical)InterleukinRetrospective cohort studySurgeryinterleukin (IL)-1Canakinumablcsh:Therapeutics. PharmacologyAutoinflammatory disorderSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory disordersAntirheumatic drugsbusinessmedicine.druganakinra
researchProduct

Investigational agents for Crohn's disease.

2010

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful en…

medicine.medical_specialtybiological therapy. Crohn' s disease. Integrins.Probiotics.Small molecules.DiseaseAdaptive ImmunityReceptors Tumor Necrosis FactorCrohn DiseaseGastrointestinal AgentsmedicineHumansImmunologic FactorsPharmacology (medical)Clinical efficacyIntensive care medicineRandomized Controlled Trials as TopicPharmacologyMitogen-Activated Protein Kinase KinasesBiological therapiesCrohn's diseaseEverolimusEnd pointINVESTIGATIONAL AGENTSbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineDrugs Investigationalmedicine.diseaseImmunity InnateImmunologyCytokinesRemission rateImmunotherapybusinessCell Adhesion Moleculesmedicine.drugExpert opinion on investigational drugs
researchProduct